For decades, the research on AChE inhibitors has been an area of interest for its role in the management of Alzheimer’s disease, and most of the drugs approved by Food and Drug Administration are AChE inhibitors [22]. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.